Lupin, Inc.

Zubair Abdul Wajid Shaikh

Venkata Poornapragnacharyulu Palle

Rajender Kumar Kamboj

Neelima Sinha

Nageswara Rao Irlapati

Gokul Keruji Deshmukh

Nilesh Raghunath Khedkar

Vijay Pandurang Karche

Kiran Chandrashekhar Kulkarni

Rahul Shripad Nandurdikar

Ravindra Babanrao Jape

The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CRor N; Y is CRor N; L is selected from &#x2014;NRC(O)&#x2014;, &#x2014;C(O)NR&#x2014; and &#x2014;NRCRR&#x2014;; Rand Rare independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).

Substituted heterocyclic compounds as CRAC modulators

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel. 

Substituted pyrazole compounds as CRAC modulators

Substituted pyridine compounds as CRAC modulators

Growing community of inventors

Maharashtra, India

Zubair Abdul Wajid Shaikh